Inspire Investor Challenges $430M Merck Deal
A shareholder slapped Inspire Pharmaceuticals Inc. with a class action in Delaware on Monday, claiming a proposed $430 million sale to Merck & Co. Inc. undervalues the company....To view the full article, register now.
Already a subscriber? Click here to view full article